Podcasts about wegovy

The Ukrainian President Volodymyr Zelensky has fired his army commander-in-chief, Oleksandr Syrskyi, in one of the biggest shake-ups of the country's military leadership since the start of Russia's full-scale invasion. General Syrskyi had clashed with the popular defence minister, Mykhailo Fedorov, whose own removal from office last week triggered rare mass protests in Ukraine. Also: France becomes the first country in the EU to ban children under the age of 15 from using social media. A special report from the school in Iran where 156 people, mostly children, were killed at the start of the US-Israeli war. As Venezuela's ousted leader Nicolás Maduro is due back in court in New York, Venezuelans tell the BBC they are too focused on trying to rebuild their lives after the earthquakes to give much thought to the criminal proceedings. The maker of Wegovy and Ozempic, Novo Nordisk, has launched legal action against its rival Eli Lilly, accusing it of false advertising in suggesting its weight-loss drugs perform better. Animal welfare experts in Britain are looking after a marmoset monkey that was found abandoned in a laundry bag on a London bus. And we look at the new developments in sleep health technology focusing on disease prediction.The Global News Podcast brings you the breaking news you need to hear, as it happens. Listen for the latest headlines and current affairs from around the world. Politics, economics, climate, business, technology, health – we cover it all with expert analysis and insight. Get the news that matters, delivered twice a day on weekdays and daily at weekends, plus special bonus episodes reacting to urgent breaking stories. Follow or subscribe now and never miss a moment. Get in touch: globalpodcast@bbc.co.ukPhoto: Ukraine's President Zelensky and now former Commander in Chief of the Ukrainian Armed Forces, Colonel General Oleksandr Syrskyi, visit an exhibition of new Ukrainian made drone-missiles Peklo in Kyiv. Credit: REUTERS/Valentyn Ogirenko

P.M. Edition for July 21. Recent AI models from China claim they're just as powerful as some of the most cutting-edge models from OpenAI and Anthropic. Journal reporter Amrith Ramkumar joins to discuss the latest reactions from Silicon Valley and the White House. Plus, General Motors had a strong second quarter as consumers kept buying pickup trucks and SUVs. And New Jersey says a software error led to almost 400 non-citizens voting in elections in the state since 2023. Alex Ossola hosts. Sign up for the WSJ's free What's News newsletter. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Behind closed doors, Sloane saw what most people never will.  Working secretly for an escort agency, she came face-to-face with the rawest, darkest sides of humanity. Now, she's pulling back the curtain, revealing her journey from sugar baby, to dancer, to escort. It's an unfiltered look into an industry often misunderstood, and rarely revealed so honestly.  HERS Thank you, HERS!  forhers.com/SECRET for your personalized, affordable care that gets you. Based on advertised cash price for 30-day supply of medication only. Membership required, fee not included, and billed separately. Weight Loss by Hers is not available in all 50 states. Wegovy® is the registered trademark of Novo Nordisk A/S. To get started and learn more, including important safety information, Wegovy® clinical study information, and restrictions, visit forhers.com. HOMECHEF For a limited time, get 50% off and free shipping for your first box PLUS free dessert for life!  HomeChef.com/SECRET.  Must be an active subscriber to receive free dessert. MINT MOBILE Make the switch! MINTMOBILE.com/SECRET PICTURES See a picture of Sloane now on Threads, Facebook, Instagram and X.  Handle: @secretroompod. YOUTUBE You can listen to The Secret Room now on YouTube! THE SECRET ROOM | UNLOCKED Susanna's mom was always deeply religious, and followed her own path to discover her connection to a higher power. When Susanna was in high school, her mom met a calm and kind man.  Who was Susanna to think her mom wasn't completely certain he was the real deal? Her new step dad and her mom were both convinced he was actually Jesus reincarnated, and that it was just a waiting game of when to tell the world he was back. And so the journey began with her new dad, Jesus, with skin on.Host: Susie Lark. The Secret Room | Unlocked is yours when you support your favorite indie podcast that could with a membership at patreon.com/secretroom, Apple Podcasts or Spotify. There's a free trial! ALL OUR SPONSORS See this week's sponsors and their offers at secretroompodcast.com/codes  FACEBOOK DISCUSSION GROUPThere's even more fun at The Secret Room Podcast Facebook Discussion Page!  Just ask to join, all are welcome. :) YOUR SECRET  Click "Share a Secret" at secretroompod.com! PODCAST TEAM Producer: Susie Lark. Story Development: Luna Patel. Music and Theme: Breakmaster Cylinder. LISTENER SURVEY Take our Listener Survey at SecretRoomPod.com!  

Plus: Novo Nordisk files a deceptive advertising lawsuit against Eli Lilly. And the latest Chinese AI model launches rattle expectations for the biggest AI players in the US. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Plus: Carl Icahn's company agrees to sell auto-service chain Pep Boys. And Ukraine strikes a deal with defense company BAE Systems to manufacture howitzers locally. Alex Ossola hosts. Sign up for WSJ's free What's News newsletter. An artificial-intelligence tool assisted in the making of this episode by creating summaries that were based on Wall Street Journal reporting and reviewed and adapted by an editor. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

I'm explaining why feeling "lazy" has nothing to do with willpower and everything to do with your metabolism, hormones, stress, and the survival mechanisms built into your body. Learn how insulin, cortisol, visceral belly fat, metabolic flexibility, and healthy habits work together to help you lose weight naturally, without guilt, shame, or punishing yourself.GET A CUSTOMIZED WEIGHT LOSS PLAN:Have a free 1-on-1 call with our Expert Nutritionists

Novo Nordisk Group General Counsel & Senior Vice President John Kuckelman speaks with Bloomberg's Dani Burger and Isabelle Lee after the company on Tuesday accused rival Eli Lilly of misleading advertising. Novo says that Lilly’s advertising campaigns rely on outdated weight-loss comparisons with lower doses of Novo’s own obesity shot Wegovy than what’s currently available, according to the complaint.See omnystudio.com/listener for privacy information.

Can you still eat at restaurants while taking Ozempic, Wegovy, Mounjaro, or Zepbound?Absolutely.One of the biggest misconceptions about GLP-1 medications is that you have to avoid restaurants, skip vacations, or order the “healthiest” item on the menu to lose weight. The truth? Long-term success comes from learning how to navigate real life—not avoiding it.In this episode, Registered Dietitian and Certified Personal Trainer, Gianna Beasley shares her simple, evidence-based strategy for eating out while staying true to your health goals. You'll learn how to build balanced meals, listen to your body's fullness cues, and enjoy restaurant meals without guilt, stress, or overthinking every bite.Whether you're headed to date night, a family dinner, a work lunch, or vacation, this episode will help you feel confident ordering at almost any restaurant while taking a GLP-1.In this episode, you'll learn:How to order at restaurants while taking a GLP-1A simple meal-building formula you can use almost anywhereWhy you don't need to avoid eating out to be successfulHow to prioritize protein without obsessing over caloriesWhat to do when you feel full halfway through your mealTips for reducing nausea or digestive discomfort when dining outHow to navigate appetizers, desserts, and drinks without guiltWhat to say when people comment on how much—or how little—you're eatingIf you've ever searched “What should I order on Ozempic?”, “Can I eat at restaurants on Wegovy?”, or “How do I eat out on a GLP-1?”, this episode is for you.

A New Zealand clinical study's found plant-based weight loss alternatives can stimulate the same hormones targeted by the likes of Ozempic and Wegovy. Calocurb researchers say participants lost an average of nearly four kilos over six months, compared with less than half a kilo for those taking a placebo. The natural GLP-1 activator is made from Kiwi hops and vegetable oil and is designed to preserve lean muscle. Calocurb CEO Sarah Kennedy told Mike Hosking it's changed the conversation around weight loss. She says it stimulates a natural hormone to make people eat less. LISTEN ABOVE See omnystudio.com/listener for privacy information.

Did you know that your body already makes its own natural version of Ozempic?In this episode, you'll hear how GLP-1 works as a natural hormone, and why drugs like Ozempic and Wegovy exist: they copy the same hormone but are designed to last much longer.You'll hear how the GLP-1 that naturally disappears from your body in two minutes got turned into an appetite-reducing drug that lasts a full week.You'll also hear about what happens to people's weight after they stop taking GLP-1 drugs, as well as what leptin resistance actually is, and whether cutting sugar can reverse it better than GLP-1 drugs. Are GLP-1 drugs for you? Or does cutting sugar give the same result?And are you ready to go deeper and ask yourself why you turn to sugar to fill an emotional need?Only you have the answer! (But I will give you a few...)To get personalized guidance to stop emotional eating and break free from sugar cravings, plus support and accountability... join the 90-day program, Freedom from Cravings Formula TODAY.For step-by-step guidance toward freedom from cravings, get your copy of my new book: "Break Free from Sugar Cravings". Available on Amazon now!For free resources, Do the Cravings Quiz and take the first step to get rid of your cravings! Download your 5 tips HERE to discover how you can get rid of cravings... even when you feel tired or stressed.To rate and review this podcast:scroll down in your podcast player on your phone and click on the stars. To leave a review, scroll down a little more and click on "Write a Review". Once you've finished, select “Send” or “Save” in the top-right corner. If you've never left a podcast review before, enter a nickname. Your nickname will be displayed on your review.After selecting a nickname, tap OK. Your review may not be immediately visible, but it should be posted soon. Thank you! - NettaDisclaimer: Information provided by Life After Sugar is not designed to and does not provide medical advice, professional diagnosis, opinion, treatment or services to you or to any other individual. This is general information for educational purposes only. The information provided ...

L'internet adore les explications simples sur l'obésité. Mangez moins, bougez plus, faites preuve de volonté. Dans cet épisode, un chirurgien bariatrique et une psychologue clinicienne expliquent pourquoi cette vision ne tient pas compte de la réalité humaine ni de la biologie. Si vous vous êtes déjà senti jugé en raison de votre poids, ou si vous vous êtes déjà reproché d'avoir repris du poids, cette conversation remplace la culpabilité par la science.Nous abordons l'obésité comme une maladie chronique influencée par la génétique, les hormones, le métabolisme, les médicaments, le stress, les mécanismes d'adaptation et un environnement rempli d'aliments peu coûteux et hyperappétents. Vous découvrirez que les interventions comme la gastrectomie en manchon et le pontage gastrique font bien plus que réduire la taille de l'estomac. Elles modifient aussi les hormones de la faim et de la satiété, notamment la ghréline et le GLP, tout en permettant de mieux comprendre des concepts comme la théorie du point d'équilibre pondéral, ainsi que les raisons pour lesquelles le corps résiste souvent à une perte de poids durable.Nous discutons également des aspects psychologiques de l'obésité, notamment l'alimentation émotionnelle, le bruit alimentaire, la stigmatisation liée au poids, les changements d'identité après la chirurgie et les raisons pour lesquelles mesurer le succès uniquement avec le chiffre sur la balance peut devenir contre-productif. Vous découvrirez aussi des stratégies concrètes, comme prioriser les protéines et les fibres pour favoriser la satiété et réduire la faim, ainsi que des approches réalistes pour bâtir des habitudes durables.Enfin, nous parlons des médicaments agonistes du GLP, 1, comme Wegovy, Ozempic, Mounjaro et Zepbound. Nous expliquons leur rôle dans le traitement de l'obésité, pourquoi ils sont souvent mal compris et pourquoi les meilleurs résultats sont obtenus lorsqu'ils sont combinés à des changements durables des habitudes de vie et à un suivi régulier.Si cette conversation vous a été utile, abonnez-vous, laissez un avis et partagez cet épisode avec une personne qui pourrait bénéficier d'une vision plus compatissante et fondée sur les données scientifiques de l'obésité.Go check out my website for tons of free resources on how to transition towards a healthier diet and lifestyle.You can download my free plant-based recipes eBook and a ton of other free resources by visiting  the Digital Downloads tab of my website at https://www.plantbaseddrjules.com/shopDon't forget to check out my blog at https://www.plantbaseddrjules.com/blog You can also watch my educational videos on YouTube at https://www.youtube.com/channel/UCMpkQRXb7G-StAotV0dmahQCheck out my upcoming live events and free eCourse, where you'll learn more about how to create delicious plant-based recipes: https://www.plantbaseddrjules.com/Go follow me on social media by visiting my Facebook page and Instagram accountshttps://www.facebook.com/plantbaseddrjuleshttps://www.instagram.com/plantbased_dr_jules/Last but not least, the best way to show your support and to help me spread my message is to subscribe to my podcast and to leave a 5 star review on Apple and Spotify!Thanks so much!Peace, love, plants!Dr. Jules 

Weight loss drugs are the new meds taking the world by storm. But if you don't want to jump on the bandwagon, what are the bog-standard, tried and true dietary changes to help you lose weight? And we're in the thick of winter - which usually means hearty stews and fatty meats are on the menu - but is there something healthier we can turn to? Nutritionist Claire Turnbull joins Tim Beveridge on the Health Hub to discuss. LISTEN ABOVESee omnystudio.com/listener for privacy information.

From Apple News In Conversation: GLP-1 drugs like Ozempic and Wegovy are being taken by millions of Americans. These medications have been approved for treating diabetes, obesity, and a small number of other chronic conditions. But even as experts are still learning how the drugs work, many people have found that they help with other disorders — from addiction to brain fog to arthritis — where anecdotal evidence is promising but the formal research hasn’t caught up. Julia Belluz, a contributing writer for the New York Times Opinion section and coauthor of Food Intelligence, joins Apple News In Conversation guest host David Greene to explain why what’s unfolding right now may be the largest uncontrolled drug experiment in modern history.

Chalene Johnson breaks down retatrutide, the peptide everyone is calling a GLP-3 and an Ozempic killer, cutting through the hype to get to what the science actually says. Eli Lilly's own clinical trials show weight loss results that beat anything semaglutide or tirzepatide has produced, but retatrutide is not FDA approved and is not legally available at any US pharmacy, which means almost nobody buying it online is actually getting the real thing. Chalene explains what retatrutide actually is (a triple agonist that adds glucagon receptor activity to the GLP-1 and GIP receptors already targeted by Ozempic, Wegovy, Mounjaro, and Zepbound), walks through what the phase three trial data really shows versus how it is being exaggerated online, and shares why an independent lab test of vials sold through TikTok, med spas, and Reddit found most contained only 7 to 14 percent of anything resembling the real molecule. She also unpacks the muscle preservation claims that are not backed by human data, the anhedonia and placebo effect reports circulating online, why bariatric surgery comparisons need context, and how to find a reputable source like Midi Health for anyone considering a GLP-1 through legitimate medical channels. Topics discussed: retatrutide, Ozempic, semaglutide, Wegovy, tirzepatide, Mounjaro, Zepbound, GLP-1, GLP-3, Eli Lilly, bariatric surgery, Midi Health, anhedonia, muscle wasting, peptides, BPC 157 Go Beyond The Podcast Join Chalene on her private podcast

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. The industry continues to forge ahead, making significant strides in scientific advancements, regulatory approvals, and strategic business developments. These moves are reshaping the landscape of drug development and patient care. Starting with Merck & Co.'s recent FDA approval for Lipfendra, the world's first oral PCSK9 inhibitor, this marks a pivotal shift in managing hypercholesterolemia. Traditionally, PCSK9 inhibitors have been administered via injection, but Lipfendra offers a more convenient oral alternative. This could significantly improve patient adherence and outcomes by easing the administration process for those managing cholesterol levels. The drug's approval highlights a crucial advancement in cardiovascular treatment, with expectations of reaching peak annual sales of $5 billion, underscoring its market potential. In another significant development, Eli Lilly has entered the burgeoning field of psychedelic therapeutics with its acquisition of Ataibeckley for up to $3.8 billion. This move reflects a growing trend toward exploring novel therapeutic avenues for psychiatric disorders. Psychedelic compounds promise new hope for patients with depression and other mental health conditions where conventional therapies have shown limited efficacy. Eli Lilly's investment signals confidence in the transformative potential of psychedelics, which could revolutionize treatment paradigms for conditions like depression and PTSD. Turning to obesity treatment, Novo Nordisk's Wegovy pill has received European Commission approval for obesity and overweight adults. As a small molecule GLP-1 receptor agonist, semaglutide enhances satiety and reduces caloric intake. This development underscores the increasing focus on metabolic disorders and highlights the competitive landscape as companies race to dominate the weight management sector with innovative oral formulations. In oncology news, Merck & Co.'s Keytruda has achieved a milestone in becoming the first PD-1 inhibitor to demonstrate phase 3 benefits as a single agent in frontline mismatch repair-deficient endometrial cancer. This success not only reinforces Keytruda's role in oncology but also emphasizes the importance of precision medicine approaches targeting specific genetic mutations in cancer therapy. The industry is also seeing substantial financial maneuvers aimed at bolstering research capabilities and market reach. Johnson & Johnson has raised its 2026 financial guidance following Tremfya's impressive $2 billion revenue milestone with its IL-23 inhibitor for autoimmune diseases. Additionally, their strategic supply chain restructuring reflects efforts to enhance operational efficiency amid a broader U.S. manufacturing push. On the regulatory front, Johnson & Johnson received UK MHRA approval for Akeega in BRCA1/2-mutated metastatic prostate cancer, highlighting ongoing focus on precision medicine and targeted therapies in oncology. Meanwhile, Medtronic's recall of Harmony Catheter Delivery Systems due to safety concerns serves as a reminder of ongoing vigilance in medical device safety regulations. In clinical trial advancements, InnoCare Pharma's TYK2 inhibitor demonstrated efficacy in a Phase 2 trial for nonsegmental vitiligo, achieving its primary endpoint and paving the way for Phase 3 studies. This highlights TYK2 inhibition as a promising strategy for autoimmune diseases like vitiligo. Moreover, we witness movements towards public offerings with companies like Vogenx and Braveheart Bio aiming for IPOs to fund their respective drug development projects. These efforts underscore the continuous drive for capital to propel innovative therapies through clinical trials and towards commercialization. Finally, turning to regulatory updates, Sanofi has entered new chapters in mRNA patent litigation against Pfizer and Moderna, reflecting ongoing tensions over intellectual property rights within the high-stakes realm of COVID-19 vaccines and mRNA technology. The outcomes here could have far-reaching implications for mRNA-based therapeutics and vaccine development. As we look at these developments collectively, they illustrate a vibrant period for pharmaceutical and biotech companies innovating new treatments while navigating complex regulatory terrains. The implications for patient care are profound, with potential improvements in therapeutic options driven by new scientific breakthroughs and strategic industry shifts. These dynamics promise to reshape the future landscape of global healthcare delivery and pharmaceutical innovation as these trends continue to unfold.Support the show

Ozempic is helping millions lose weight—but what if it's also causing a hidden form of muscle loss most people never see coming?"Ozempic feet" has become a viral term, but the real concern isn't just how your feet look—it's what rapid weight loss may be doing to your muscle mass, strength, metabolism, and long-term health.In this eye-opening episode of Accelerated Health with Sara Banta, I uncover the truth behind Ozempic muscle loss, why it happens, who is most at risk, and the science-backed strategies to rebuild lean muscle while protecting your health.If you're taking Ozempic, Wegovy, Mounjaro, or another GLP-1 medication—or considering one—this is information you need before your next step.Supplements Featured In This Episode:• Accelerated Liver Care® https://www.acceleratedhealthproducts.com/products/accelerated-liver-care • Acceleradine® Iodine https://www.acceleratedhealthproducts.com/products/acceleradine-iodine-supplement • Accelerated Thyroid® https://www.acceleratedhealthproducts.com/products/accelerated-thyroid-supplement • Accelerated Fast®  https://www.acceleratedhealthproducts.com/products/accelerated-fast-supplement • Accelerated Ancient Salt® https://www.acceleratedhealthproducts.com/products/accelerated-ancient-salt-4-oz Not sure what food to eat and avoid? This guide is for you.⬇️

In this series, Going Deep, we’ll be doing bite-sized explorations into the most interesting industries, businesses and economic events… in Australia and around the world. For today's episode, we're diving into the weight loss drug economy - a $58 billion industry built on injections that hack your hunger signal. We've seen food companies scramble to reformulate their products, airlines calculate what lighter passengers mean for their fuel bill and gyms completely rewrite their pitch. In this episode, we'll explore how Ozempic and Wegovy went from diabetes treatments to cultural phenomena…and what a world of meaningfully lighter people actually means for business, public health, and your hip pocket. _ Note: This recording took place in February 2026. All numbers noted were accurate as of this date. Want to lean how to go from a Saver to Investor in just 7 days - watch our new series here Download the free app (App Store): http://bit.ly/FluxAppStore Download the free app (Google Play): http://bit.ly/FluxappGooglePlay Daily newsletter: https://bit.ly/fluxnewsletter Flux on Instagram: http://bit.ly/fluxinsta Flux on TikTok: https://www.tiktok.com/@flux.finance —- The content in this podcast reflects the views and opinions of the hosts, and is intended for personal and not commercial use. We do not represent or endorse the accuracy or reliability of any opinion, statement or other information provided or distributed in these episodes. ____See omnystudio.com/listener for privacy information.

Few prescription drugs have generated as much excitement as the new generation of weight-loss drugs, commonly called “GLP-1” medications. You've probably heard about Ozempic, Wegovy, Zepbound, and Mounjaro, even if you don't want to lose weight.In this episode: How do these drugs work? How to deal with the sometimes-unpleasant side effects? What has the GLP-1 family of drugs been proven to do, and what could they be used for in the future? Plus, details about a new Medicare program that now covers these drugs when prescribed for weight loss for those who qualify.Not a Checkbook member? ⁠⁠⁠⁠⁠⁠Sign up for a free 30-day trial to access all of our unbiased ratings⁠⁠⁠⁠⁠⁠.

GLP-1 drugs like Ozempic and Wegovy are being taken by millions of Americans. These medications have been approved for treating diabetes, obesity, and a small number of other chronic conditions. But even as experts are still learning how the drugs work, many people have found that they help with other disorders — from addiction to brain fog to arthritis — where anecdotal evidence is promising but the formal research hasn’t caught up. Julia Belluz, a contributing writer for the New York Times Opinion section and coauthor of Food Intelligence, joins Apple News In Conversation guest host David Greene to explain why what’s unfolding right now may be the largest uncontrolled drug experiment in modern history.

Vivian dives into the "thinness economy" and the surprising ways weight bias can affect your finances, career, and earning potential. From GLP-1 medications like Ozempic and Wegovy to workplace discrimination, social media beauty standards, and the booming weight loss industry, this episode explores the uncomfortable intersection of money, health, and appearance. In this episode, you'll learn: 1. How weight bias impacts hiring, salaries, promotions, and long-term wealth, why obesity is a disease rather than a moral failure, and the hidden economic costs of discrimination. 2. The real financial tradeoffs of GLP-1 medications, including who can actually afford them, what insurance does and doesn't cover, and whether these drugs are a financial investment or simply another expensive response to societal pressure. 3. How the "thinness economy" is reshaping entire industries… from grocery stores and restaurants to airlines, fashion, and healthcare, and what these shifts mean for your wallet and the future of consumer spending. Follow the podcast on Instagram and TikTok! Got a financial question you want answered in a future episode? Email us at podcast@yourrichbff.com Learn more about your ad choices. Visit podcastchoices.com/adchoices

Weight-loss drugs like Ozempic and Wegovy are one of the fastest growing pharmaceuticals. But as newer GLP-1 medications hit the market, questions remain about side effects, health equity and the cultural impact. On today's In the Loop, we ask: what have we learned so far about the popular drug? And how have GLP-1s changed the way we think about health and weight loss?GUESTS: Dr. Micah Eimer, cardiologist, clinical assistant professor of medicine in the division of cardiology at Northwestern University Feinberg SchoolDavid D. Kim, PhD, assistant professor of medicine and public health sciences at University of ChicagoRachelle Lacroix Mallick, registered dietician and nutritionist with a focus on reproductive healthFor a full archive of In the Loop interviews, head over to wbez.org/intheloop.

Free Ozempic?! Eat Your Way to the GLP-1 Effect + Why Women Are Hungry with guest expert Dominique Ludwig - #66Want Ozempic Fx without the Rx?What if the answer to better energy, fewer cravings, improved hormones, and sustainable weight management isn't another diet… but relearning how to eat?This week Samantha sits down with leading clinical nutritionist and No Nonsense Nutrition author Dominique Ludwig to unpack what really drives hunger, “food noise,” cravings, blood sugar swings, and the changes women experience through midlife and menopause. Together they break down the science behind naturally supporting satiety hormones like GLP-1, why calorie counting may not be the answer, and how simple shifts can completely change your relationship with food.This conversation is practical, evidence-informed, and refreshingly free of extremes.In this episode you'll learn:Discover the real biological reason cravings, fatigue, and midsection weight gain might not be a willpower issue at allFind out how to naturally activate the same hormone behind Ozempic and Wegovy — using your dinner plateLearn the Triple 30 Method and why these three specific numbers matter more than ever in midlifeUncover why calorie counting misses the point — and what to focus on insteadHear the honest truth about who GLP-1 medications are (and aren't) right forGet the science behind why a handful of nuts may not "cost" you as many calories as you thinkUnderstand the surprising gut-to-hormone pathway that connects fiber to estrogen balanceLearn what actually happens in your body during the "invisible" metabolic shift after 40Discover the real difference between mindful snacking and "grazing" — and why it mattersFind out how to judge protein powder, fermented foods, and resistant starch without the overwhelmAbout Our Guest:Dominique Ludwig is one of the UK's leading nutritionists, with an MSc in Nutrition from King's College London and over 30 years of clinical experience supporting more than 4,500 people worldwide.A Registered Nutritional Therapy Practitioner and Fellow of the British Association of Nutrition and Lifestyle Medicine, she is the author of the instant #1 Sunday Times bestseller No-Nonsense Nutrition, and the founder of the Renew Reset Recharge® and Triple 30 programs. Her work has been featured in The Sunday Times, The Telegraph, and SheerLuxe.

Send us Fan MailFREE — SEE WHERE YOUR PRACTICE IS BLEEDING REVENUE IN 3 MINUTES Take the RECOVER Diagnostic Quiz: https://eligibility.natrevmd.com/recover-quiz-lp More free resources: https://natrevmd.com/trusted-resources/ Payment Posting Audit Checklist: https://eligibility.natrevmd.com/payment-posting-checklistWE ARE RE-AIRING THIS EPISODE BECAUSE IT MATTERS RIGHT NOW. On July 1, 2026, the Medicare GLP-1 Bridge went live. Every independent practice with Medicare patients on Wegovy, Zepbound KwikPen, or Foundayo for weight management is now facing retrospective prior authorizations routed through a central processor most billing teams have never worked with. The AMA released physician guidance on June 26. The workflow is new. The documentation burden is heavier than most practices have modeled. And prior auth was already the fastest-growing revenue threat independent practices face. In this episode Dr. Heather walks through: WHAT WE COVER Why prior auth denials are silently eating clinical time and revenue The dollar amount your practice is losing every month (and how to calculate it) The 5-step workflow to manage prior auth without drowning your team What every practice needs to change this week "Prior auth has a dollar amount attached to it. Most practices never calculate it." THREE ACTIONS THIS WEEK 1. Calculate what prior auth is costing your practice in staff hours, denied claims, and clinical time 2. Set up a central prior auth tracker (do not run this out of email threads) 3. Train the team on the Medicare GLP-1 Bridge central processor workflow before the backlog compounds

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into the latest news and insights that are shaping the landscape of patient care and drug development. The U.S. FDA has expanded the label for Pfizer and Astellas' Padcev, in combination with Merck's Keytruda, to include all muscle-invasive bladder cancer patients. This significant regulatory update broadens access to a combination therapy that merges an antibody-drug conjugate with a PD-1 inhibitor, offering enhanced treatment options for patients unable to tolerate cisplatin, a common chemotherapy drug. The decision marks a pivotal step forward in providing more inclusive and effective treatment regimens for bladder cancer. In Scotland, Roche's Columvi has been endorsed by the Scottish Medicines Consortium for use in treating relapsed or refractory diffuse large B-cell lymphoma. This approval highlights the growing importance of bispecific antibodies in oncology, which can simultaneously engage two different antigens to enhance anti-tumor responses. Such innovations underscore the ongoing transformation of cancer treatment through combination therapies. Across the Atlantic, Health Canada has approved Clinuvel's Scenesse for erythropoietic protoporphyria (EPP), a rare condition causing extreme light sensitivity. Scenesse acts as a melanocortin receptor agonist, offering photoprotection and improving quality of life for those affected by this debilitating disorder. On the business front, Bayer's strategic partnership with Apollo has secured a €3 billion equity deal for its long-acting reversible contraceptives business. This move underscores a growing emphasis on women's health and contraceptive innovation. Likewise, CMS and Insilico's collaboration aims to harness artificial intelligence for CNS drug discovery, promising to accelerate drug development through AI-driven target identification. Clinical trials continue to reveal promising developments. Eisai's Etalanetug is showing potential in reducing tau tangle biomarkers in dominantly inherited Alzheimer's disease. Similarly, Eisai and BioArctic's Leqembi subcutaneous autoinjector demonstrates comparable efficacy to its intravenous counterpart, potentially improving compliance and accessibility for early Alzheimer's patients through less invasive administration methods. Financially, Apnimed is planning an IPO to support its sleep apnea pill's commercial launch, while Velogene Biotechnology has secured Series A funding to advance its gene-editing platform. These financial activities highlight ongoing investments in innovative solutions aimed at addressing unmet clinical needs. Yet, challenges persist as well. The FDA has rejected Hengrui and Elevar Therapeutics' combination treatment for hepatocellular carcinoma for a third time, emphasizing the difficulties of meeting regulatory standards and demonstrating efficacy. Additionally, Germany's new healthcare cost-saving law has doubled pharmaceutical rebate rates, sparking industry concern over potential impacts on profitability and innovation investment. The regulatory landscape continues to evolve with the FDA proposing streamlined registration processes under the "hub-and-spoke" model to enhance transparency and security within supply chains. Meanwhile, recent FDA transparency actions have led to the release of 14 drug rejection letters, underscoring ongoing challenges in securing approvals due to stringent regulatory requirements. Geographically, emerging biotech hubs like Basel and Beijing are gaining prominence as global talent hotspots due to their conducive environments for research and development collaboration. These regions are becoming increasingly attractive for biopharmaceutical innovation. Amid fierce competition in obesity management solutions, Lilly's launch of its oral GLP-1 receptor agonist Foundayo faces stiff competition from Novo Nordisk's Wegovy pill. The race reflects broader trends toward developing patient-centric therapies that offer convenience alongside therapeutic efficacy. Intellectual property strategies are also evolving as companies employ new patent tactics to maintain competitive advantages in crowded markets. Safety remains a top priority as exemplified by Lupin Pharmaceuticals' recall of contaminated eye drops, highlighting ongoing challenges in ensuring product safety. Lastly, advancements in wearable technology offer promising improvements in patient care; however, integration into clinical practice is met with infrastructural hurdles—a sentiment echoed by healthcare professionals surveyed by the AMA. Overall, these developments paint a complex picture of scientific innovation intersecting with regulatory evolution and strategic industry adaptations aimed at enhancing patient outcomes while navigating economic pressures. As the industry evolves, stakeholders must remain vigilant and adaptable to seize opportunities and address challenges effectively.Support the show

Professor Donal O'Shea, HSE National Clinical Lead on Obesity

South Africa's weight loss jab boom has a dark underside. A Pretoria pharmacy, iDexis, was producing roughly 84,500 units of semaglutide a month — more than Novo Nordisk's entire local sales of Ozempic and Wegovy — under the guise of a one-off "compounding" exemption meant for individual patients. Regulators only inspected the premises this year, more than two years after Novo Nordisk first complained, and found no sterile ventilation, no batch records, and no adverse-event tracking. Elsewhere, the Public Investment Corporation has suspended CEO Patrick Dlamini over an alleged Lanseria Airport conflict of interest, its fifth executive suspension in two years.

Recent studies say that somewhere between 12 and 16 percent of Americans have used GLP-1s like Ozempic, Wegovy, or Zepbound. Many people who take these drugs report that the meds have fundamentally changed their relationship to food. Jason Diamond is a writer who covers food, men's fashion, and culture. Throughout his life he's had a complicated relationship with both food and medication, which played a big role in how he thought about whether or not, as a new dad, to start taking GLP-1s.  Jason's story in New York Magazine is “Eating With My Daughter and My Zepbound.” The Sporkful production team includes Dan Pashman, Emma Morgenstern, Andres O'Hara, Kameel Stanley, and Jared O'Connell. Right now, Sporkful listeners can get three months free of the SiriusXM app by going to siriusxm.com/sporkful. Get all your favorite podcasts, more than 200 ad-free music channels curated by genre and era, and live sports coverage with the SiriusXM app. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

(00:00:00) 224: DOCs Itchy&Bitchy Answer YOUR Questions - Global Edition! (00:00:11) Welcome to Itchy and Bitchy (00:00:42) Doc Itchy Medical Pets Supplements (00:02:32) Hormone Replacement and GLP-1: Navigating Medical Decisions (00:08:06) Brain Fog and Alzheimer's: When to Worry (00:11:11) Menopause in Dogs: A Misunderstanding (00:16:48) The Truth About Alcohol Consumption (00:22:10) GLP-1 and Addiction: A Complex Discussion (00:27:41) Probiotics: The Unknown Frontier (00:32:05) Closing Thoughts on Supplements and Health Ask Docs Itchy&Bitchy:Your Questions on Weight, Hormones, and the GLP-1 additction ...You're writing in from everywhere, and your questions don't hold back, so neither will we. Why is your dog carrying extra weight even though nothing about mealtime has changed? On the human side: does Ozempic actually rewire your brain's reward system, not just your appetite? Emerging research says GLP-1 drugs quiet the same dopamine pathway that drives cravings for food, alcohol, and drugs which raises a wild question we're tackling this season: could a diabetes drug end up treating addiction? We're also digging into whether "Ozempic personality changes" are real, why weight-loss drugs hit women differently at midlife, and what nobody's telling you about pet supplements.Got a question? Send it — nothing's off limits.Visit itchyandbitchy.comBecome a supporter of this podcast: https://www.spreaker.com/podcast/itchy-bitchy-podcast--4303608/support.Itchy & Bitchy: Have you felt dismissed, misdiagnosed, or gaslit by a broken medical system.  From gut health, hormones, autoimmune disease, chronic pain, holistic health, and alternative medicine ... medical gaslighting, patient advocacy , or misdiagnosis we'll call that too.  For chronic illness warriors, self-advocacy seekers: WE OFFER  No BS 

Has your weight loss suddenly stopped on Ozempic, Wegovy, Mounjaro, or Zepbound?If the scale hasn't moved in weeks and you're wondering whether your GLP-1 has stopped working, you're not alone. Weight loss plateaus are one of the most common—and frustrating—parts of the GLP-1 journey.The good news? A plateau doesn't automatically mean you've done something wrong or that your medication has failed.In this episode, Registered Dietitian, Certified Personal Trainer, and GLP-1 expert Gianna explains why weight loss plateaus happen, what your body is actually doing, and the evidence-based questions she asks clients before making any changes.We'll cover:What actually counts as a weight loss plateauWhy weight loss naturally slows over timeThe difference between normal weight fluctuations and a true stallCommon reasons GLP-1 weight loss plateaus happenHow protein, hydration, fiber, sleep, stress, and movement influence progressWhy eating less isn't always the answerWhen it may be time to talk with your healthcare providerThe mindset shift that helps you move through a plateau without panicIf you've been asking yourself, “Why did my weight loss stop on Ozempic?” or “Why isn't my GLP-1 working anymore?” this episode will help you understand what may be happening and what to focus on next.

Today we're tackling one of the hottest topics in medicine, nutrition, and weight loss. GLP-1 medications.You know them by names like Ozempic, Wegovy, Mounjaro, and Zepbound. You've seen the commercials.You've heard the celebrity stories. You probably know someone taking one. Maybe you're taking one yourself.These medications have transformed the conversation around weight loss, and for many people they have been life-changing. But they've also raised some important questions. Can we naturally stimulate our own GLP-1? And now, Can fasting provide some of the same benefits?And is the future of weight management medication, lifestyle, or a combination of both? Fasting & GLP-1

Coming up, Wegovy weight loss pills are now available in pharmacies and online in the UK. Will they help tackle obesity? Plus, how scientists are trying to restore sensation in the feet; the legacy of Dolly the sheep 30 years on; and space rovers and the solar eclipse with the astronomer Megan Argo. Like this podcast? Please help us by supporting the Naked Scientists

In the western world, richer people tend to be thinner – especially women. But does wealth make people thin, or does being thin make them wealthy? And could the rise of weight-loss drugs such as Mounjaro and Wegovy give people – especially women – greater control over their economic outcomes? Soumaya speaks to Harvard professor Rebecca Diamond, the author of a new working paper that finds female users of GLP-1 drugs are more likely to find jobs and romantic partners. Soumaya also speaks to FT consumer editor (and GLP-1 user) Claer Barrett to discuss the drugs' effects on consumer habits – and the economy at large.Subscribe to Soumaya's show on Apple, Spotify, Pocket Casts or wherever you listen.Further reading: The economics of women's weightDoes the weight-loss revolution show up in the data?The challenges of a weight-loss economyPresented by Soumaya Keynes. Produced by Mischa Frankl-Duval. Original music and sound design by Breen Turner. Andrew Georgiades is the broadcast engineer. Manuela Saragosa is the executive producer. Flo Phillips if the FT's head of audio.Read a transcript of this episode on FT.com Hosted on Acast. See acast.com/privacy for more information.

This week on "The Top Line," we’re covering some of the biggest stories across biopharma before turning to one of the industry’s major scientific meetings of the summer. First, we discuss Vertex’s $10 billion acquisition of Crinetics Pharmaceuticals, the company’s largest deal to date, and what it says about Vertex’s push beyond its historic strength in cystic fibrosis. We also cover growing scrutiny from U.S. lawmakers over the industry’s use of clinical trials in China. Then, Fierce Pharma Senior Editor Fraiser Kansteiner recounts his recent trip to New Orleans for the American Diabetes Association’s 2026 Scientific Sessions with Fierce Pharma Marketing’s Zoey Becker. For years, ADA has focused heavily on its eponymous indication, but this year’s meeting made clear how much the conversation is evolving, with obesity data from drugmakers of all stripes taking up more of the spotlight. Topics include the biggest data sets from the meeting, what it was like to sit down with Novo Nordisk’s new CEO for the first time and the latest from Insulet’s Marvel collaboration on a line of comics about an Omnipod-wearing superheroine. To learn more about the topics in this episode: Vertex, in its largest-ever deal, acquires endocrine disease specialist Crinetics for $10B As US lawmakers increase scrutiny of Chinese trials, industry fears ‘huge distraction and expense’ ‘I’m a lot more optimistic today’: Mike Doustdar tells Fierce about pivotal first year as Novo Nordisk CEO ADA: Lilly pulls back curtain on impressive triple-G efficacy in patients with obesity, diabetes ADA: Amgen highlights Repatha perks, GLP-1 pitfalls in push to boost cardiometabolic pedigree With ADA in the books, analyst says Lilly is ‘widening its lead’ in the obesity race ADA: Novo's Wegovy pill reaches new GLP-1 patients with impressive 3M prescription milestone ADA: Tolerability ‘not to be underappreciated’ in Roche, Zealand’s amylin obesity prospect ADA: Boehringer execs claim survodutide tolerability 'consistent' with class despite phase 3 update ADA: Lilly posts oral semaglutide-topping data as Foundayo speeds toward 2nd potential nod in diabetes This week's episode is sponsored by IQVIA Biotech. Built for biotech innovators, IQVIA Biotech is a full-service CRO, designed for agility, fast decisions, and the urgency needed for emerging biopharma. With dedicated teams and deep therapeutic expertise, we help move programs forward with focus and confidence. Visit IQVIABiotech.comSee omnystudio.com/listener for privacy information.

Is Ozempic secretly slowing down your thyroid? Millions are using GLP-1 medications like Ozempic for weight loss and blood sugar control, but very few people are being warned about what they could be doing to their thyroid health.If you're experiencing fatigue, hair loss, brain fog, cold hands and feet, constipation, or stubborn weight loss plateaus after starting Ozempic, your thyroid may be sending you warning signs that are often overlooked.In this eye-opening episode of Accelerated Health with Sara Banta, I uncover the surprising connection between Ozempic, GLP-1 medications, and thyroid function, why standard thyroid testing may miss the problem, and the essential nutrients your thyroid needs to function properly.If you're taking Ozempic, Wegovy, Mounjaro, or another GLP-1 medication, this is information you don't want to miss.Supplements Featured In This Episode:• Acceleradine® Iodine https://www.acceleratedhealthproducts.com/products/acceleradine-iodine-supplement • Accelerated Liver Care® https://www.acceleratedhealthproducts.com/products/accelerated-liver-care• Accelerated Thyroid® https://www.acceleratedhealthproducts.com/products/accelerated-thyroid-supplement Not sure what food to eat and avoid? This guide is for you.⬇️

In this episode of Girl Talk with Tay, I sit down with Bracha Banayan, family nurse practitioner, entrepreneur, and founder of IVDrips and Hello Dose, for one of our most fascinating conversations yet. We dive into the science behind GLP-1 medications, why they're about so much more than weight loss, and how they're changing the conversation around longevity, metabolic health, and healthy aging.Bracha explains how GLP-1s work in the body, why weight gain is often rooted in biology rather than willpower, and how factors like glucose, insulin, inflammation, and hormones all play a role in long-term health. We also discuss who may benefit from GLP-1 medications, including women navigating perimenopause and menopause, adults focused on cardiovascular health, and those looking to improve metabolic wellness.We also get into fertility, blood sugar, continuous glucose monitors, and the surprising ways GLP-1s may help reduce cravings by working on the brain's reward system. Beyond medications, Bracha shares the foundational habits she believes everyone should prioritize first from walking after meals and getting morning sunlight to improving sleep and building sustainable wellness routines.Whether you're curious about GLP-1s, trying to better understand metabolic health, or looking for practical ways to optimize your health for the long run, this episode is packed with insights and actionable takeaways.xo, Tay⸻Follow Bracha Banayan!

Questions, comments? Shoot me a text.Everyone's Talking About GLP-1s... But I Think We're Missing the Bigger ConversationEverywhere you turn, someone is talking about Ozempic, Wegovy, or Zepbound.Maybe your sister is taking one.Maybe your best friend has lost weight on one.Maybe you've even caught yourself wondering..."Am I the only one who still wants to lose weight without medication?"If that's where you are, this episode is for you.This isn't an anti-GLP-1 conversation.It's a bigger conversation.We're talking about what happens when your body changes after 50, why so many women feel like "nothing works anymore," and the one thing I believe we've stopped talking about.If you've ever felt confused by your hunger, frustrated by the scale, or like your body has become a complete mystery...I want to offer you a different way to think about it.Because what if the problem isn't that your body has stopped working...What if you've just never been given the translation guide?Join Hangry to HealthyWebsite: The Simplicity of WellnessTransformation Starts Here: Schedule Your ConsultFollow Me on TikTokFollow Me on Instagram

The US are out of the World Cup after defeat by Belgium - even though one of their star players was on the pitch after his automatic one-match ban for a red card was suspended. President Trump admitted he'd intervened. Also: BBC Eye finds evidence of torture and sexual violence at detention centres for Ukrainians in Russia and occupied Ukraine. The story of a 12-year-old pulled alive from the rubble following two earthquakes in Venezuela. The body of Iran's former supreme leader is paraded through the streets of Tehran. Millions turn out to pay their last respects. The weight-loss drug, Wegovy, is now available in pill form in Britain. And if you thought China was over-populated - think again.The Global News Podcast brings you the breaking news you need to hear, as it happens. Listen for the latest headlines and current affairs from around the world. Politics, economics, climate, business, technology, health – we cover it all with expert analysis and insight. Get the news that matters, delivered twice a day on weekdays and daily at weekends, plus special bonus episodes reacting to urgent breaking stories. Follow or subscribe now and never miss a moment. Get in touch: globalpodcast@bbc.co.uk Photo: US fan with face painted in national colours in Portland, Oregon. Credit: IMAGN IMAGES via Reuters/Denny Medley.

As a marijuana grower for a startup South American based company, Jake did some questionable things. Like the time he smuggled 500 marijuana plants through customs! Get into the weeds with us, and hear all of Jake's exploits.   HERS Thank you, HERS!  forhers.com/SECRET for your personalized, affordable care that gets you. Based on advertised cash price for 30-day supply of medication only. Membership required, fee not included, and billed separately. Weight Loss by Hers is not available in all 50 states. Wegovy® is the registered trademark of Novo Nordisk A/S. To get started and learn more, including important safety information, Wegovy® clinical study information, and restrictions, visit forhers.com. HOMECHEF For a limited time, get 50% off and free shipping for your first box PLUS free dessert for life!  HomeChef.com/SECRET.  Must be an active subscriber to receive free dessert. MINT MOBILE Make the switch! MINTMOBILE.com/SECRET PICTURES See pictures of the pirate grow shipping container, Sofia, the baby plants and the full legal facility in South America! They are waiting for you on Threads, Facebook, Instagram and X.  Handle: @secretroompod. YOUTUBE You can listen to The Secret Room now on YouTube! THE SECRET ROOM | UNLOCKED Host: Susie Lark. The Secret Room | Unlocked is yours when you support your favorite indie podcast that could with a membership at patreon.com/secretroom, Apple Podcasts or Spotify. There's a free trial! ALL OUR SPONSORS See this week's sponsors and their offers at secretroompodcast.com/codes  FACEBOOK DISCUSSION GROUPThere's even more fun at The Secret Room Podcast Facebook Discussion Page!  Just ask to join, all are welcome. :) YOUR SECRET  Click "Share a Secret" at secretroompod.com! PODCAST TEAM Producer: Susie Lark. Story Development: Luna Patel. Music and Theme: Breakmaster Cylinder. LISTENER SURVEY Take our Listener Survey at SecretRoomPod.com!  

Before EP Description: Learn about the Healing Power of Prolonged Fasting: HEREWhat if losing weight on a GLP-1 drug and losing weight through fasting produce the same number on the scale, but nearly opposite effects inside your cells?Host Dr. Katie Deming believes some of the most popular weight loss drugs on the market may be quietly blocking one of your body's most essential repair processes. Not because they're failing to work, but because they work in a way that keeps your body in a state it was never meant to stay in.She takes an honest, no-shame look at GLP-1 drugs like Ozempic and Wegovy and compares what's actually happening inside your body when you lose weight on them versus when you fast. The scale might show the same number. The story underneath is very different. Dr. Katie explains a repair switch your body can only flip when your stomach is genuinely empty, and why keeping it perpetually fed may keep that switch turned off for good. She connects the dots between mitochondrial health, cellular cleanup, visceral fat, muscle preservation, and metabolic flexibility in a way that's clear, honest, and direct.She's not here to shame anyone taking these medications. She gets why people reach for something that works. But she shares what happened when several of her patients who were certain they'd go right back on the drug after fasting decided they didn't want to, and why.Chapters:00:04:23 - The Food System Is Broken00:06:13 - Your Body Needs Empty Space00:08:24 - GLP-1s May Block Repair Mode00:10:41 - Weight Loss Is Not Healing00:12:26 - What Cancer Cells Feed On00:13:30 - Fasting Changes the Terrain00:17:00 - Cleaning Out Damaged Mitochondria00:18:00 - The Most Dangerous Fat00:20:35 - The Hidden Muscle Loss Problem00:22:20 - Clients Who Were on GLP-1s Before Fasting00:26:06 - Who Should Never Water Fast If you've ever wondered whether weight loss and true healing are actually the same thing, or why one of her patients gained lean mass six weeks after a 14-day water fast, this episode will change how you think about what your body actually needs.Press play and learn why the repair process your body is waiting to run may only start when you finally stop feeding it.Join Dr. Katie's 3-Day Guided Fast, for expert support, daily live calls, and a community to fast alongside: Sign-Up Follow Dr. Katie Deming on InstagramWatch on YoutubeDISCLAIMER: The Born to Heal Podcast  is intended for informational purposes only and is not a substitute for seeking professional medical advice, diagnosis, or treatment. Individual medical histories are unique; therefore, this episode should not be used to diagnose, treat, cure, or prevent any disease without consulting your healthcare provider.A thought-provoking podcast explores cancer through the lens of holistic medicine and functional medicine, discussing causes of cancer, metabolic health, and unconventional approaches like water fasting, fasting and autophagy, and detox, while weighing fasting benefits against chemo side effects and radiation side effects, sharing stories of a cancer survivor navigating chemotherapy, natural medicine, holistic healing, and even spiritual healing on the path toward cancer remission and holistic health. 

In this episode, I'm talking about why so many attempts to change your relationship with food seem to fizzle out, even when you're motivated and genuinely want things to be different. Because constantly starting over doesn't mean you're lazy, uncommitted, or missing some magical piece of information. We're digging into the deeper reasons certain behaviors stick around, what they may actually be doing for you, and why curiosity is often far more helpful than criticism.  This conversation goes beyond meal plans and motivation and gets into the questions that most people never think to ask. Quotes "We don't lead with the question, what do we do about this? We lead with the question, what is this actually all about? It's the question that changes everything when someone is really willing to look at it, because the answer is usually not what you think it is." "Most of us are so focused on fixing the behavior that we haven't stopped to ask what the behavior is doing." "The reason change feels so hard isn't because you're weak; it's because something would have to be given up if you changed. Meaning, if the behavior is protective in some way, shape, or form, it's providing something for you." "You don't need to know the answer yet. The key is starting to think about this and removing the blame that we're pointing at ourselves and starting to ask questions." "Sometimes this isn't something that you can do alone, and that's where you might need a real person like a therapist or a dietician. Sometimes we need people who can see the patterns that we're too close to see." Frequently Asked Questions Why do I keep failing when I try to change my eating habits? Repeatedly struggling with food does not necessarily mean you lack motivation or discipline. Many behaviors serve a purpose, and understanding what they are providing can help create lasting change.   Why do I sabotage myself around food? What feels like self-sabotage is often a protective pattern. Behaviors around food may be helping you cope with emotions, stress, shame, or fear, even when those behaviors are no longer serving you well.   Why is giving up dieting so scary? For many people, dieting feels tied to safety, control, belonging, or fear of weight gain. Letting go of those rules can bring up emotions and beliefs that deserve attention and support.   What does fear of weight gain really mean? Fear of weight gain often goes beyond the number on the scale. It can be connected to shame, past experiences, fears of rejection, or beliefs about worth and acceptance.   Why do I feel stuck between wanting recovery and wanting to stay the same? Feeling pulled in two directions is called ambivalence, and it is a normal part of recovery. Having conflicting feelings does not mean you're doing anything wrong.   Does structured eating help with disordered eating? Structured eating provides consistency and helps create a foundation for healing. Many people benefit from eating regularly throughout the day rather than relying on hunger cues alone in the early stages of recovery.   Do I need a therapist or a dietitian for eating disorder recovery? Support can be helpful when you're too close to your own patterns to see them clearly. A therapist or dietitian can help you understand what is driving your behaviors and provide practical tools for recovery. Resources Be sure to sign up for my weekly newsletter! Brave on Purpose! - Grab my new book here! Grab my Journal Prompts Here! Looking for a speaker for an upcoming event? Let's chat! Now accepting new clients! Find out if we're a good fit!    Episodes Mentioned: -Episode 45. Basics of Intuitive Eating -Episode 122. Ozempic, Wegovy, & Mounjaro with Laura Cipullo -Episode 133. GLP with Dr. Kim Dennis -Episode 160. Intuitive Eating Updates You Need to Know with Elyse Resch MS, RDN, CEDS-C, Fiaedp, FADA, FAND   LEAVE A REVIEW + help someone who may need this podcast by sharing this episode. Be sure to sign up for my weekly newsletter here! You can connect with me on Instagram @rachelleheinemann, through my website www.rachelleheinemann.com, or email me directly at rachelle@rachelleheinemann.com

Morse code transcription: vvv vvv All you need to know about Wegovy weight loss tablet Prince Harry to stay at Buckingham Palace for part of UK trip, his spokesperson says Man who spent 500k to clear his name rejected for compensation Australian PM apologises for inappropriate comments about Kylie Minogue UK fighter jets intercept Russian plane over Norwegian Sea Teenagers cleared of murdering 15 year old boy in sword attack Inquiry into care of Norfolk man arrested after crocodile attack The dark side of the Brazilian butt lift boom Pizza Express held inquiry into Andrew Mountbatten Windsors Woking claim Wolf Alice cover Nirvana at emotional homecoming show

Thought your GLP-1 medication would completely eliminate sugar cravings?If you're taking Ozempic, Wegovy, Mounjaro, or Zepbound and still find yourself craving chocolate, sweets, chips, or your favorite snacks, you're definitely not alone.The truth is, cravings are much more complex than most people realize—and having cravings doesn't automatically mean your medication has stopped working.In this episode, Registered Dietitian and Certified Personal Trainer, Gianna breaks down the science behind food cravings, explains why they can still happen while taking a GLP-1, and shares practical, evidence-based strategies to help you better understand what your body may be trying to tell you.We'll cover:Why you may still crave sugar while taking a GLP-1The difference between hunger, cravings, and food noiseHow under-eating can actually increase cravingsWhy protein matters—but isn't the entire solutionThe impact of sleep, stress, and daily habits on cravingsWhy emotional eating can still happen on a GLP-1How years of habit can influence what you craveWhen cravings may be worth discussing with your healthcare providerIf you've ever wondered, “Why am I still craving sugar on Ozempic?” or worried that cravings mean your medication has stopped working, this episode will help you understand what's actually happening—and how to respond with curiosity instead of guilt.

After England's World Cup game against Mexico, Will Bain speaks to one publican who's just closed up at 5am after screening the match.Separately, an interview with the prime minister of Luxembourg, who tells Wake Up to Money that a new Defence, Security and Resilience Bank should be established for NATO countries.Plus, Novo Nordisk's new once-daily weight-loss pill becomes available in the UK today - what might it do to the market?

Broadcast from KSQD, Santa Cruz on 7-02-2026: Dr. Dawn devotes the first half of the show to a nuanced defense of GLP-1 receptor agonists, arguing the polarized debate treats obesity as a moral failure rather than a physiological one. She recounts the "Marilyn Monroe dress" moment that transformed semaglutide from diabetes drug into elite cosmetic tool, and pushes back on the puritanical framing that behavior change must be earned rather than pharmacologically enabled—noting we don't apply this logic to antihypertensives or statins. Dr. Dawn catalogs visceral fat as a genuine endocrine organ producing over 17 hormones, most of which drive self-perpetuating growth: leptin (this satiety hormone at high levels disables it's own brain receptor), IL-6, TNF-alpha (blocks insulin), resistin (increases insulin resistance and inflammation), PAI-2 (blocks clot breakdown, raising cardiovascular risk), retinol-binding protein 4 (impairs muscle glucose uptake), chemerin (recruits macrophages and directs fat to the belly), and visfatin. Only adiponectin declines with rising visceral fat. It improves insulin sensitivity, suppresses hepatic gluconeogenesis, and blocks IL-6 . Dr. Dawn describes GLP-1's neurobiological action: receptors in the hypothalamus, brainstem, hippocampus, and mesolimbic reward system, with the drugs quieting the brain's salience network so food loses its intrusive pull. Taste buds shift, sweet and salty become muted, and reward circuits stop firing on cheat foods—creating a window during which behavioral change becomes possible. Dr. Dawn frames group support through self-determination theory (autonomy, competence, relatedness), arguing GLP-1s create the cognitive bandwidth for behavioral programs to succeed. A Tufts study of patients discontinuing after 10% weight loss found those enrolled in behavioral support programs regained about three times less weight than usual-care controls, outperforming even medically-tailored meal plans. Group engagement doubled the time patients stayed on the medication. A November 2025 Nature study piggybacked on deep brain stimulation research at Penn. Electrodes implanted in the nucleus accumbens of post-bariatric patients recorded low-frequency brain activity surges during food-noise episodes on drug free patients. A third participant who started tirzepatide showed complete silencing of that signature—the first direct electrical confirmation that GLP-1s suppresses compulsive food thoughts in the reward center. RNA sequencing of adipose tissue from 25 obese patients before and after bariatric surgery, compared to 24 lean controls, revealed persistent epigenetic changes even after weight loss. Lipid-associated inflammatory macrophages drop but retain some of their pro-inflammatory epigenetics, explaining the well-known slippery slope back to obesity—and why Dr. Dawn suggests GLP-1s may work best as intermittent tools when behavioral maintenance starts slipping. An emailer asks about long-term smoking versus vaping data. Dr. Dawn notes there is no long-term data yet, but short-term evidence shows e-cigarettes contain nicotine, propylene glycol, reactive oxygen species, and nitrosamines, producing spirometry readings similar to mild COPD in otherwise-healthy vapers. Vaping over a year raises stroke relative risk by 1.62 and nearly doubles MI risk, and combining smoking and vaping produces a multiplicative rather than additive harm. Data on cancer will take decades to emerge. Researchers built a functioning underwater breathing apparatus for cockroaches with electrodes attached to brain and sensory organs allowing remote-controlled direction while preserving natural obstacle-navigation autonomy. The 10mm × 10mm sponge-based oxygen tank uses magnesium dioxide catalyzing hydrogen peroxide breakdown, delivering oxygen through silicone tubes to the roach's spiracles for up to three hours underwater. Deployemenet will improve search-and-rescue in flooded and collapsed structures where dogs cannot reach. A Science Advances paper from Yong Lin Kong's lab at Rice University describes 3D-printing electronic circuits directly onto living tissue. Researchers achieved microwave-focused annealing at sub-200-micrometer resolution. By selectively heating only conductive ink particles (copper, silver, gold) without damaging surrounding tissue, the technique enables printing circuits onto 3D-printed heart valves, tracheas, and ear scaffolds, potentially creating combined graft-and-sensor implants, ingestible diagnostic devices, and perhaps even decorative electronic tattoos. A single-shot reformulation of zanamivir (originally the inhaled flu drug Relenza) provided 76.1% flu protection in a 5,000-participant trial—far exceeding the roughly 40-45% offered by annual flu vaccines. Because zanamivir targets neuraminidase in a way that inactivates it if the virus tries to mutate around the drug, trapping newly-made viral copies inside their host cells, this approach works across all flu strains and could bypass the annual guessing game of trivalent vaccine formulation.

You stopped the weightloss shot, and the cravings came roaring back. Maybe you're scared it means the shot was the only thing that ever worked for you. In this episode, Corinne breaks down what Ozempic, Wegovy, and the other GLP-1 shots are actually doing, what they're not doing, and why the food noise comes back, sometimes not until after you've hit your goal weight. You'll hear why this isn't a willpower problem, what the eating was always trying to tell you, and one thing you can start doing tonight to figure out the real reason you reach for food. Whether you're on the shot, off it, or scared to ever start, this one's for you.   Get my free PDF — The 30-Second Question That Quiets Food Noise: https://www.nobsweightloss.com/30second

Amanda and Amye break down the latest headlines from reality shows you love (and hate?)Timestamps are approximate:9:00 90 Day Fiance22: Sister Wives24: Secret Lives of Mormon Wives30: Love After Lockup 33: Mcbee DynastyGET BONUS CONTENTUnlock ad-free episodes and exclusive bonus recaps by joining our community!Patreon: patreon.com/littlemissrecap (50% your first month through the month of June!Website: littlemissrecap.com/supportSUPPORT OUR SPONSORSHers now offers access to an affordable range of FDA-approved GLP-1 medications, including the Wegovy pill and the Wegovy pen. Visit forhers.com/LMR to get personalized, affordable care that gets you. OUR OTHER SHOWS & MERCHTrue Crime: Hear our latest documentary deep-dives on Murder She Watched at murdershewatchedpod.comShop Merch: Get your podcast gear at littlemissrecap.threadless.comBuy my book: https://www.amazon.com/Fat-Girl-Skinny-Amye-Archer/dp/B0H6NSD6VJ/CONNECT WITH USInstagram: @littlemissrecapFacebook Group: Little Miss Recap Podcast CommunityYouTube: Watch our recaps hereContact: email littlemissrecap@gmail.com Hosted on Acast. See acast.com/privacy for more information.

View the Show Notes Page for This Episode Become a Member to Receive Exclusive Content Sign Up to Receive Peter's Weekly Newsletter In this "Ask Me Anything" (AMA) episode, Peter explores the effects of GLP-1 receptor agonists—including drugs such as Ozempic, Wegovy, and Zepbound—with a particular focus on their impact on muscle. He examines how much lean mass people actually lose during treatment and how those changes compare to weight loss achieved through other methods, while explaining why measurements of lean mass on DEXA scans can sometimes be misleading. Peter discusses the effects of these medications on bone mass, fracture risk, strength, and physical function, highlighting why functional outcomes may be more important than body composition metrics alone. He also explores how GLP-1–based therapies affect different fat depots throughout the body, identifies who may be most vulnerable to muscle loss, and outlines practical strategies for preserving muscle and bone health while using these medications. Finally, Peter reviews early insights into retatrutide, a next-generation weight-loss therapy, including what current evidence suggests about its effects on weight loss and muscle mass. If you're not a subscriber and are listening on a podcast player, you'll only be able to hear a preview of the AMA. If you're a subscriber, you can now listen to this full episode on your private RSS feed or our website at the AMA #86 show notes page. If you are not a subscriber, you can learn more about the subscriber benefits here. We discuss: The evolution of GLP-1 receptor agonists from diabetes drugs to breakthrough weight-loss therapies [1:45]; Early concerns about lean mass loss with GLP-1 receptor agonists and the limitations of clinical trial data [3:45]; How newer research has changed the understanding of lean mass loss on GLP-1 receptor agonists and why DEXA measurements can misrepresent muscle loss [6:15]; Comparing lean mass loss across semaglutide, tirzepatide, and traditional weight-loss interventions [10:30]; Comparing lean mass loss from GLP-1 receptor agonists with bariatric surgery, and whether these drugs cause muscle loss beyond normal expectations from substantial weight loss [13:15]; The limited evidence regarding the timing of lean mass loss during GLP-1 therapy and the implications for exercise and nutrition strategies [16:00]; Body composition changes after stopping GLP-1 receptor agonists: weight regain, fat regain, and lean mass recovery [17:45]; Why lean mass measurements are an imperfect proxy for muscle health and function [21:45]; The effects of GLP-1 receptor agonists on bone mineral density, fracture risk, and the importance of resistance training [23:00]; Do GLP-1 receptor agonists directly cause muscle loss or simply mimic the effects of calorie restriction? [26:00]; Why strength and physical function often improve despite lean mass loss on GLP-1 receptor agonists [28:00]; Who is most at risk for lean mass loss during GLP-1–induced weight loss? [34:45]; Intramuscular fat (IMAT), DEXA limitations, and the challenge of measuring true muscle loss [37:00]; Preserving muscle while losing weight: resistance training, protein intake, and emerging research on preserving muscle during GLP-1–induced weight loss [39:00]; Resistance-training principles for preserving lean mass during GLP-1–induced weight loss [43:45]; Managing side effects and prioritizing protein intake while training on GLP-1 receptor agonists [46:15]; Retatrutide: early evidence on its effects on weight loss, lean mass, and muscle function, as well as the limitations of the data being collected in ongoing clinical trials [48:00]; The risks of using gray-market retatrutide before FDA approval [52:15]; Key takeaways [54:30]; and More. Connect With Peter on Twitter, Instagram, Facebook and YouTube

More Americans are using GLP-1 drugs, like Ozempic and Wegovy, for weight loss, and that's impacting their grocery shopping habits. A new survey finds that GLP-1 use could shave up to 2.7% off grocery store sales this year. So, how are food companies adapting? Also on the program: a preview of major Supreme Court decisions coming up and a frank conversation about the costs of being in a wedding party, courtesy of the Marketplace podcast "This Is Uncomfortable."Every story has an economic angle. Want some in your inbox? Subscribe to our daily or weekly newsletter.Marketplace Morning Report is more than a radio show. Check out our original reporting and financial literacy content at marketplace.org — and consider making an investment in our future.Stories featured in this episode:Would you go broke for a bachelorette?

It's Episode 22 of Season 24. Enter the dark waters of the Cape Fear River as we present tales about diabolical distractions."Please, No Smoking" by Sam Conn Pantle (Story starts around 00:03:50)Produced by Jeff ClementCast: Eddie - James Solis, Casey - Dan Zappulla"The Extra Ones" by Don Tobin (Story starts around 00:19:35)Produced by Claudius MooreCast: Albert - Graham Rowat, Mrs. Holloway - Mary Murphy, Man - Peter Lewis"Debunked" by Quincy Lee (Story starts around 00:44:10)TRIGGER WARNING!Produced by Jesse CornettCast: Max - Erin Lillis, Pete - Jesse Cornett, Nathan - Atticus Jackson, Woman - Linsay Rousseau, Sarah - Nichole Goodnight"The Doll" by Joseph Yenkavitch (Story starts around 01:16:00)Produced by Phil MichalskiCast: Narrator - Tanja Milojevic, Mom - Sarah Ruth Thomas, Girl - Nichole Goodnight"The Early Bus" by Liam Rose Philipson (Story starts around 01:50:00)TRIGGER WARNING!Produced by Phil MichalskiCast: Narrator - Jeff Clement, Jake - Matthew Bradford, Carlos - Dan Zappulla, Daniel - Kyle Akers, Big Kid #1 - Atticus Jackson, Big Kid #2 - Elie Hirschman, Mister Critter - Mike DelGaudio, Driver - Peter LewisThis episode is sponsored by:Home Chef - Home Chef's meal kits are rated #1 in quality, convenience, value, taste, and recipe ease. Head to homechef.com/nosleep to get 50% off and free shipping for your first box plus free dessert for life!Betterhelp - This episode is sponsored by BetterHelp. Take a step towards a better you. Our listeners get 10% off their first month at betterhelp.com/nosleep.Weight Loss by Hims - Ready to reach your weight loss goals? Weight Loss by Hims and WegovyÆ. Get a personalized, affordable plan that gets you. Go to Hims.com/nosleep.Click here to learn more about The NoSleep Podcast teamClick here to learn more about Quincy Lee Executive Producer & Host: David CummingsMusical score composed by: Brandon Boone"The Early Bus" illustration courtesy of Kelly TurnbullThe NoSleep Podcast is Human-made for Human Minds. No generative AI is used in any aspect of work.Audio program ©2026 - Creative Reason Media - The copyrights for each story are held by the respective authors. No duplication or reproduction of this audio program is permitted without the written consent of Creative Reason Media. No part of this audio program may be used or reproduced in any manner for the purpose of training artificial intelligence technologies or systems. All rights reserved.

Love island obsessed Kevin and his lady Marcelle try to make Whitney like something popular and it goes perfectly weirdly. Whitney tries to figure out the physiological profile of each contestant based on their photos alone, and we dissect this new form of emotion porn and that reality tv may just be mama for women Tickets for The Big Baby Tour https://www.whitneycummings.com SHOP: https://whitneycummings.com/index.html#store Thank you to our sponsors! Square #ad Get up to $200 off Square hardware when you sign up at https://square.com/go/WHITNEY! #squarepod Jones Road Beauty #ad Use code GOODFORYOU at https://www.jonesroadbeauty.com to get a Free Gift with your first purchase! #JonesRoadBeauty #ad OLIPOP #ad Get a free can of OLIPOP: buy any 2 cans of OLIPOP in store, and they'll pay you back for one. Works on single cans of any flavor, any retailer. Get yours at https://drinkolipop.com/WHITNEY. OLIPOP is available in the soda aisle and with the chilled beverages at thousands of retailers nationwide, including Walmart and Target. Hers #ad Ready to reach your goals? Visit https://www.forhers.com/whitney to get personalized, affordable care that gets you. That's F-O-R-H-E-R-S dot com slash whitney forhers.com slash whitney Weight Loss by Hers is not available in all 50 states. Wegovy® is the registered trademark of Novo Nordisk A S. To get started and learn more, including important safety information, Wegovy® clinical study information, and restrictions, visit https://www.forhers.com. Bellesa EVERYONE who signs up wins a FREE toy or gift card! https://www.shopbboutique.co/vibe/goodforyou-yt